

Lupin announces acquisition of Renascience in the United Kingdom

03 April 2025 | News

Allows Lupin to further enhance its branded medicine portfolio



Lupin Healthcare (UK) Limited, the wholly owned subsidiary of Mumbai-based global pharma major Lupin Limited has announced the acquisition of Renascience Pharma Limited, a United Kingdom (UK)-based pharmaceutical company and sole supplier of 4 specialty products targeting unmet medical needs in the UK.

With this acquisition, Lupin Healthcare (UK) Limited gains full ownership of Renascience which, going forward, will trade as its subsidiary. The portfolio includes branded injectable cephalosporines for infectious diseases, a topical treatment for ear pain and a branded quinazoline-like diuretic for cardio-vascular and renal indications.

Commenting on the acquisition, Fabrice Egros, President Corporate Development, Lupin said, "In recent years Lupin has established a highly successful branded business in the UK delivering significant value to patients and the NHS (National Health Service). This strategic move allows Lupin to further enhance our branded medicine portfolio, catering to unmet medical needs and furthering our mission to provide accessible and sustainable healthcare solutions."

Co-founder & Director of Renascience, Eric Che commented, "Renascience was founded with the goal to improve patient access to speciality, critical medicines and we are extremely proud of what we have been able to revive to date for the benefit of patients. As we looked forward to the future, it was deeply important that Renascience has the best opportunity to build on what has been accomplished and expand its reach to improve outcomes for as many patients as possible, and we are pleased to have found that opportunity with Lupin. Lupin has the cultural fit, capabilities and experience for the next stage of

growth, and we are excited to see the products go from strength to strength.”